Trials / Completed
CompletedNCT04348266
RFA for GIM Treatment
Efficacy of Radiofrequency Ablation in Treatment of Gastric Intestinal Metaplasia: a Randomized, Self-control Study
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- King Chulalongkorn Memorial Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Use radiofrequency ablation (RFA) for Gastric intestinal metaplasia (GIM) treatment.
Detailed description
Gastric intestinal metaplasia (GIM) is a pre-malignant lesion. Currently, there is no standard treatment for this condition, thus the patients with GIM need surveillance endoscopy every 1-3 years, regarding to the severity and extension of lesion. However, the protocol for GIM surveillance is uncertain and need high cost. Radiofrequency ablation (RFA) is used for Barrett's esophagus (BE; pre-malignant lesion of esophageal adenoCA) treatment as a standard treatment. The investigators hypothesized that RFA may effective in GIM treatment. The investigators will random GIM participants to have the RFA treatment only one site of the stomach (left or right). At the first session, the investigators will biopsy at suspected GIM lesions to confirm the diagnosis and severity of GIM. Two months later, The investigators will apply RFA to all GIM lesions at the assigned location and then every 2 months for 3 sessions or until no GIM lesion seen by endoscopy. The final endoscopy will be done at 1 year follow-up and biopsy will be performed to assess the efficacy of RFA compare to no treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Radiofrequency ablation (RFA) | Radiofrequency ablation is a device that can generate the heat from radiofrequency for tissue ablation. RFA is a standard treatment for Barrett' esophagus and high grade dysplasia in esophagus. |
Timeline
- Start date
- 2020-06-01
- Primary completion
- 2023-02-28
- Completion
- 2023-05-31
- First posted
- 2020-04-16
- Last updated
- 2023-08-01
Locations
1 site across 1 country: Thailand
Source: ClinicalTrials.gov record NCT04348266. Inclusion in this directory is not an endorsement.